SNAP 25 antibodies inhibiting SNARE complexes and uses thereof

By providing SNAP 25 antibodies with specific amino acid sequences, binding to TAT peptides, inhibiting the formation of SNARE complexes, the problem of insufficient antibody research in the prior art is solved, and the effect of effectively improving and treating skin wrinkles is achieved.

CN118924645APending Publication Date: 2024-11-12NANJING HAWU TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411190642.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-10-16
Filing Date
2020-10-14
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the prior art, there is insufficient research on antibodies that inhibit SNARE complexes, and it is difficult to effectively inhibit their formation, affecting the improvement and treatment of skin wrinkles.

Method used

Provided is a SNAP 25 antibody comprising a specific amino acid sequence, including light chain and heavy chain variable regions, that binds to TAT peptides, to inhibit the formation of the SNARE complex and to express the antibody in cells by recombinant expression vectors, for preparation of Cosmetics, medicines and health foods.

Benefits of technology

Effectively inhibiting the formation of SNARE complexes, improving or treating skin wrinkles, demonstrating the cellular permeability and skin delivery ability of anti-SNAP 25 antibodies, significantly inhibiting MMP-1 collagenase activity and reactive oxygen generation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924645A_ABST
    Figure CN118924645A_ABST
Patent Text Reader

Abstract

The invention relates to an anti-SNAP 25 antibody for inhibiting an SNARE complex and application of the anti-SNAP 25 antibody, relates to the technical field of SNAP 25 antibody protein screening, and relates to an anti-SNAP 25 antibody containing a heavy chain CDR and a light chain CDR with specific sequences or an antigen binding fragment of the anti-SNAP 25 antibody. The anti-SNAP 25 antibody is expected to inhibit formation of an SNARE complex, so that the anti-SNAP 25 antibody can be effectively applied to improvement or treatment of skin wrinkles.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of SNAP 25 antibody protein screening, and more particularly to SNAP 25 antibodies that inhibit SNARE complexes and uses thereof. Background Art

[0002] Membrane fusion that occurs inside cells is caused by proteins called SNARE (soluble N-ethylmaleimide sensitive factor attachment protein receptor). SNARE proteins refer to a specific group of proteins that are very well conserved among all protein types, and the SNARE complex (or "complex") refers to the complex of these proteins. SNARE proteins can be divided into target (t-)SNARE and vesicular (v-)SNARE. t-SNARE refers to SNARE proteins present in the presynaptic membrane, and v-SNARE refers to SNARE proteins present in synaptic vesicles. t-SNARE is composed of an integral membrane protein called syntaxin 1A and SNAP 25 (soluble NSF attachment protein of 25 kDa) as a peripheral membrane protein, and its functional unit is considered to be its complex (t-SNARE complex). v-SNARE refers to a membrane protein called vesicle-associated membrane protein 2 (VAMP2 or synaptobrevin). These SNARE proteins have a site of about 60 aa to 70 aa called the "SNARE core", which aggregates with each other to form a four-helical bundle called the SNARE complex.

[0003] Although studies related to the SNARE complex have been actively conducted, the reality is that studies on antibodies that inhibit the SNARE complex are still insufficient.

[0004] Therefore, how to provide a SNAP 25 antibody that inhibits the SNARE complex is a technical problem that those skilled in the art need to solve urgently. Summary of the invention

[0005] In view of this, the present invention is proposed.

[0006] One of the purposes of the present invention is to provide an application of a protein that inhibits the SNARE complex.

[0007] A second object of the present invention is to provide a SNAP25 antibody.

[0008] A third object of the present invention is to provide a fusion antibody.

[0009] A fourth object of the present invention is to provide a composition.

[0010] A fifth object of the present invention is to provide biological materials.

[0011] In one aspect, an embodiment of the present invention provides the use of a protein that inhibits the SNARE complex in the preparation of a cosmetic for preventing or improving skin wrinkles. The protein that inhibits the SNARE complex comprises an antibody against SNAP 25; the antibody comprises:

[0012] 1) a light chain variable region, comprising a light chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO.1, a light chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO.2, and a light chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO.3;

[0013] 2) a heavy chain variable region, comprising a heavy chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO.4, a heavy chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO.5, and a heavy chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO.6;

[0014] 3) Fc region, wherein the sequence of the Fc region is the sequence of the Fc constant region of any antibody that binds to the SNAP 25 protein.

[0015] It should be noted that the Fc segment is the constant region of the antibody. The amino acid sequence of the Fc segment is the same in different antibodies of the same protein. Therefore, the Fc segment sequence in the present invention is the Fc segment sequence in any antibody that binds to the SNAP 25 protein in the prior art.

[0016] Another aspect of the present invention provides a SNAP 25 antibody, which is the protein sequence.

[0017] The third aspect of the present invention provides a fusion SNAP 25 antibody, comprising a fragment of the TAT peptide shown in SEQ ID NO.7 combined with the antibody.

[0018] Another aspect of the present invention provides a nucleic acid molecule encoding an antibody.

[0019] At the same time, the present invention also provides a biomaterial, comprising:

[0020] 1) a recombinant expression vector comprising the nucleic acid molecule;

[0021] 2) Cells transformed with the recombinant expression vector described in 1).

[0022] As the same concept as the above technical solution, the present invention also provides a cosmetic composition for preventing or improving skin wrinkles, wherein the active ingredient includes the antibody.

[0023] An antioxidant cosmetic composition, characterized in that it comprises the antibody.

[0024] A composition for diagnosing skin pigmentation diseases, characterized in that it comprises the antibody.

[0025] A pharmaceutical composition for preventing or treating skin wrinkles, characterized in that it comprises the antibody.

[0026] Technical Effects

[0027] The present invention relates to an anti-SNAP 25 antibody that inhibits the SNARE complex and its use, and more specifically, the present invention relates to an anti-SNAP 25 antibody or an antigen-binding fragment thereof comprising a heavy chain CDR and a light chain CDR of a specific sequence. The anti-SNAP 25 antibody is expected to inhibit the formation of the SNARE complex, and thus can be effectively used to improve or treat skin wrinkles. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0029] Attached Figure 1 The results of ELISA analysis for screening SNAP 25 scFv antibodies are shown in Figure 2.

[0030] Attached Figure 2 The size and protein purity of the cell-permeable SNAP 25 scFv antibody protein were obtained by SDS-PAGE.

[0031] Attached Figure 3The results are obtained by analyzing the ability of cell-permeable SNAP25scFv antibody protein to inhibit the formation of SNARE complex by native-PAGE.

[0032] Attached Figure 4 The results show that the cell-permeable SNAP 25scFv antibody protein inhibits the activity of MMP-1 collagenase.

[0033] Attached Figure 5 The results of Western blotting show the cell permeability of the cell-permeable anti-SNAP 25 scFv protein.

[0034] Attached Figure 6 Shown are the results of the porcine skin permeability of the cell-permeable anti-SNAP 25 scFv protein obtained by DAB staining. DETAILED DESCRIPTION

[0035] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0036] The present invention provides a SNAP 25 antibody, comprising:

[0037] A light chain variable region, comprising a light chain CDR1 composed of the amino acid sequence shown in SEQ ID NO.1, a light chain CDR2 composed of the amino acid sequence shown in SEQ ID NO.2, and a light chain CDR3 composed of the amino acid sequence shown in SEQ ID NO.3;

[0038] The heavy chain variable region includes a heavy chain CDR1 composed of the amino acid sequence shown in SEQ ID NO.4, a heavy chain CDR2 composed of the amino acid sequence shown in SEQ ID NO.5, and a heavy chain CDR3 composed of the amino acid sequence shown in SEQ ID NO.6.

[0039] The Fc region has a sequence that is a sequence of the Fc constant region of any antibody that binds to the SNAP 25 protein.

[0040] In addition, the present invention provides a fusion anti-SNAP 25 antibody or an antigen-binding fragment thereof that further binds to the TAT peptide shown by SEQ ID NO.7.

[0041] YGRKKRRQRRR, SEQ ID NO. 7;

[0042] The base sequence encoding the TAT peptide is TATGGCCGCAAAAAACGCCGCCAGCGCC GCCGC, SEQ ID NO.8.

[0043] In the present invention, the term "antibody" refers to a protein molecule that acts as a receptor that specifically recognizes an antigen, including immunoglobulin molecules that are immunologically reactive with a specific antigen, and examples thereof may include monoclonal antibodies, polyclonal antibodies, full-length antibodies, and all of antibody fragments. In addition, the term "antibody" may include bivalent or bispecific molecules (e.g., bispecific antibodies), double antibodies, three antibodies, or four antibodies.

[0044] In the present invention, the term "monoclonal antibody" refers to an antibody molecule consisting of a single molecule obtained from a substantially identical antibody group, and unlike polyclonal antibodies that can bind to multiple epitopes, this monoclonal antibody exhibits a single binding and affinity to a specific epitope. The term "full-length antibody" in the present invention refers to a structure having two light chains of the entire length and two heavy chains of the entire length, wherein each light chain is connected to the heavy chain by a disulfide bond. The heavy chain constant region has gamma (γ), muon (μ), alpha (α), delta (δ) and epsilon (ε) types, and has gamma 1 (γ1), gamma 2 (γ2), gamma 3 (γ3), gamma 4 (γ4), alpha 1 (α1) and alpha 2 (α2) as subclasses. The constant region of the light chain has kappa (κ) and lambda (λ) types. The subtypes of IgG include IgG1, IgG2, IgG3 and IgG4.

[0045] In the present invention, the term "heavy chain" may include both the variable region VH and the full-length heavy chain and its fragments, wherein the variable region VH includes an amino acid sequence having a variable region sequence sufficient to confer specificity to an antigen, and the full-length heavy chain and its fragments include three constant regions CH1, CH2 and CH3. In addition, in the present invention, the term "light chain" may include both the full-length light chain and its fragments, wherein the full-length light chain and its fragments include the variable region VL and the constant region CL, wherein the variable region VL includes an amino acid sequence having a variable region sequence sufficient to confer specificity to an antigen.

[0046] In the present invention, the terms "fragment", "antibody fragment" and "antigen-binding fragment" refer to any fragment of the antibody of the present invention that has the antigen-binding function of the antibody and can be used interchangeably. Exemplary antigen-binding fragments include Fab, Fab', F(ab')2 and Fv, etc., but are not limited thereto.

[0047] The term "nucleic acid molecule" used in this specification has a comprehensive meaning including DNA (gDNA and cDNA) and RNA molecules, and the nucleotides as the basic building blocks of nucleic acid molecules include not only natural nucleotides, but also analogs with modified sugar or base moieties. The sequence of the nucleic acid molecule encoding the heavy chain variable region and the light chain variable region of the present invention may be modified, and the modification includes the addition, deletion or non-conservative substitution or conservative substitution of nucleotides.

[0048] In addition, the present invention provides a recombinant expression vector comprising the nucleic acid molecule.

[0049] In the present invention, "vector" refers to a self-replicating DNA molecule used to carry cloned genes (or other fragments of cloned DNA).

[0050] In the present invention, the term "expression vector" refers to a recombinant DNA molecule comprising a targeted coding sequence and a suitable nucleic acid sequence necessary for expressing the coding sequence connected in an operable manner in a specific host organism. Preferably, the expression vector may contain more than one selective marker. The marker is generally a nucleic acid sequence having a characteristic that can be selected by a chemical method, and all genes that can distinguish cells transformed by traits from cells transformed by non-trait belong to this. Examples thereof include antibiotic resistance genes such as ampicillin, kanamycin, geneticin (G418), bleomycin, hygromycin and chloramphenicol, but are not limited thereto and can be appropriately selected by those skilled in the art.

[0051] In order to express the DNA sequence of the present invention, any of a variety of expression control sequences can be used in the vector. Examples of useful expression control sequences can include, for example, early and late promoters of SV40 or adenovirus, promoters and enhancers of CMV, LTR of retrovirus, lac system, trp system, TAC system or TRC system, T3 promoter and T7 promoter, major operator genes and promoter regions of lambda phage, regulatory regions of fd encoding proteins, promoters of 3-phosphoglycerate kinase or other glycolytic enzymes, promoters of the phosphatase (e.g., Pho5), promoters of yeast α-mating system, and known gene expression control sequences of prokaryotic cells or eukaryotic cells or their viruses and other sequences derived therefrom and various combinations thereof.

[0052] A vector system that simultaneously expresses light chains and heavy chains in one vector or a system that expresses light chains and heavy chains on separate vectors can be a vector for expressing the antibodies of the present invention. In the latter case, the two vectors are introduced into the host cell by co-transformation and targeted transformation. Co-transformation is a method of simultaneously introducing each vector DNA encoding the light chain and the heavy chain into the host cell, and then screening for cells that fully express the light chain and the heavy chain. Targeted transformation is a method of screening cells transformed with a vector trait containing a light chain (or heavy chain), and then transforming the screened cells expressing the light chain again with a vector containing a heavy chain (or light chain), thereby finally screening for cells that fully express the light chain and the heavy chain.

[0053] In addition, the present invention provides a cell transformed using the recombinant expression vector trait.

[0054] The cells capable of stably and continuously cloning and expressing the vector of the present invention may be any host cell known in the relevant technical field, including, for example, Escherichia coli, Bacillus strains such as Bacillus subtilis and Bacillus thuringiensis, Streptomyces, Pseudomonas (e.g., Pseudomonas putida), Proteus mirabilis, or Staphylococcus (e.g., Staphylococcus carnosus) and other prokaryotic host cells, but are not limited thereto.

[0055] In the method for preparing the antibody or antigen-binding fragment thereof, the culture of the transformed cells can be carried out according to suitable culture media and culture conditions known in the relevant technical field. A person of ordinary skill in the art can easily adjust and use such a culture process according to the selected strain. Cell culture is divided into suspension culture and adherent culture according to the growth mode of the cells, and is divided into batch culture, fed-batch culture and continuous culture according to the culture method. The culture medium used for culture should appropriately meet the required conditions of the specific strain.

[0056] In addition, the present invention provides a cosmetic composition for preventing or improving skin wrinkles, comprising the antibody. Specifically, the composition can inhibit the formation of SNARE complexes.

[0057] Furthermore, the present invention provides an antioxidant cosmetic composition comprising the antibody.

[0058] In addition to the active ingredients, the cosmetic composition may further contain conventional auxiliary agents such as stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers.

[0059] The dosage form of the cosmetic composition can be prepared as any dosage form commonly prepared in the art, and can have a dosage form selected from the group consisting of skin external ointment, cream, soft lotion, nutritious lotion, facial mask, essence, hair tonic, shampoo, conditioner, hair conditioner, hair care agent, gel, skin lotion, softener, toner, firming water, skin care water, lotion, moisturizing milk, nutritious water, massage cream, nutritious cream, eye cream, moisturizing cream, hand cream, foundation, nutritious essence, sunscreen, soap, cleansing foam, cleansing milk, cleansing cream, body lotion and shower gel, but not limited thereto. The composition of these various dosage forms can contain appropriate various basic raw materials and additives required for the formulation of the dosage form, and those skilled in the art can easily select the type and amount of these ingredients.

[0060] In case the dosage form is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicon dioxide, talc or zinc oxide etc. can be used as the carrier component.

[0061] When the dosage form is a powder or a spray, lactose, talc, silicon dioxide, aluminum hydroxide, tricalcium silicate or polyamide powder can be used as a carrier component. In particular, when the dosage form is a spray, a propellant such as chlorofluorocarbon, propane / butane or dimethyl ether can be additionally contained.

[0062] When the dosage form is a solution or an emulsion, a solvent, a solubilizer or an emulsifier is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol oil, glycerol fatty esters, polyethylene glycol or fatty acid esters of sorbitan.

[0063] When the dosage form is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitan ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth can be used as a carrier component.

[0064] In addition, the present invention provides a health food composition for preventing or improving skin wrinkles, which comprises the antibody. Specifically, the composition can inhibit the formation of SNARE complexes.

[0065] The health food composition can be provided in the form of powder, granules, tablets, capsules, syrups, beverages or pills, and the health food composition can also be used together with other foods or food additives in addition to the composition according to the present invention as an effective ingredient, and can be appropriately used according to a common method. The mixed amount of the active ingredient can be appropriately determined according to its purpose of use (for example, according to the treatment of prevention, health care or treatment).

[0066] The effective dose of the antibody or antigen-binding fragment thereof contained in the health food composition can be used in accordance with the effective dose of the pharmaceutical composition, but in the case of long-term intake for the purpose of health and hygiene or for the purpose of health conditioning, it can be used in an amount below the above range, but since there is no problem with the safety of the active ingredient, it can indeed be used in an amount above the above range.

[0067] The type of health food is not particularly limited, and examples thereof may include meat, sausage, bread, chocolate, candy, snacks, biscuits, pizza, instant noodles, other noodles, chewing gum, dairy products (including ice cream), various soups, beverages, tea, functional drinks, alcoholic beverages, and vitamin complexes, etc.

[0068] In addition, the present invention provides a pharmaceutical composition for preventing or treating skin wrinkles, comprising the antibody. Specifically, the composition can inhibit the formation of SNARE complex.

[0069] The pharmaceutical composition of the present invention may additionally include a pharmaceutically acceptable carrier, which is a carrier commonly used as a preparation, including lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, but is not limited thereto. In addition to the above-mentioned components, the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, etc.

[0070] The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenterally administered, the pharmaceutical composition can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, intrapulmonary administration, and rectal administration. In the case of oral administration, since proteins or peptides are digested, oral compositions can be formulated in a manner that coats the active agent or prevents decomposition in the stomach. The composition of the present invention can be administered by any device that can move the active substance to the target cells.

[0071] The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, diet, administration time, administration route, excretion rate and reaction sensitivity, and an ordinarily skilled physician can easily determine and prescribe a dosage effective for the desired treatment or prevention.

[0072] The pharmaceutical composition of the present invention can be formulated using pharmaceutically acceptable carriers and / or excipients according to methods that can be easily implemented by a person skilled in the art to which the present invention belongs, so as to be prepared into a unit volume form or prepared to be loaded into a multi-volume container. In this case, the dosage form can be a solution, suspension or emulsion in an oil or aqueous medium, or can also be a concentrate, powder, suppository, powder, granule, tablet or capsule form, and can further include a dispersant or stabilizer.

[0073] The compositions of the invention may be administered as the sole therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with existing therapeutic agents.

[0074] Embodiments of the invention

[0075] The present invention will be described in more detail below by way of examples. These examples are only used to more specifically describe the present invention, and according to the gist of the present invention, the scope of the present invention is not limited to these examples, which is obvious to those skilled in the art to which the present invention belongs.

[0076] Example 1 Screening of SNAP 25 scFv Antibodies

[0077] 1. Perform bio-panning

[0078] Using a 7.6×10 9 Bio-panning was performed using the OPAL library of 1000 m2 of diversity. 4 μg of SNAP 25 antigen was immobilized on epoxy magnetic beads and the input phage was reacted. Phage reacted with the antigen were eluted and the output titer was measured. The input and output titers were measured each time to obtain information about the bio-panning and to confirm whether the bio-panning was performed normally. ≥4×10 12The number of colonies / mL of phage is taken as the input phage. It can be seen that the output is from the first time to 5×10 6 Colony count / mL, 2nd time - 5×10 8 Colony count / mL, 3rd time - 1.7×10 7 Bio-panning was performed based on the number of colonies / mL.

[0079] 2.ELISA analysis

[0080] ELISA analysis was performed to screen for highly sensitive and specific antibodies. The obtained phage was used to infect E. coli and smeared on an LB plate supplemented with antibiotics. After culturing in an incubator at 30°C for 16 hours, the resulting colonies were randomly collected. After each colony was cultured in LB medium, it was treated with isopropyl-β-D-thiogalactoside (IPTG) to express scFv, and the E. coli was lysed to extract the soluble fraction, and ELISA was performed. First, 1ug / mL of SNAP 25 recombinant protein was fixed to a 96-well ELISA plate and blocked with phosphate buffered saline (PBS) containing 1% bovine serum albumin (BSA). One hour later, the cell lysate obtained above was treated and reacted at 4°C for 16 hours. After washing the plate three times with PBS containing 0.1% Tween 20, HRP conjugated anti-HA antibody was diluted 1:1000 in blocking solution and reacted at room temperature for 1 hour. The plate was washed five times with PBS containing 0.1% Tween 20, then developed with TMB substrate, and the scFv antibody bound to the antigen was measured using an ELISA reader. The results were obtained by Figure 1 As shown, 288 antibodies were analyzed, and an optical density value (OD) of 0.4 was arbitrarily selected as a positive guideline, and an optical density value (OD) of 0.1 was selected as a negative guideline to screen 9 antibodies.

[0081] Example 2 Sequencing of SNAP 25 scFv Antibody

[0082] For the 9 positive clones of SNAP 25 antibody screened by ELISA analysis, individual clones were screened by sequencing. Sequencing was required because there may be duplicate clones in the positive clones screened previously. According to the sequencing results, 6 of the 9 positive clones were confirmed to be individual clones for SNAP 25 antibody protein.

[0083] Example 3 Preparation of cell-permeable SNAP 25 scFv antibody protein

[0084] 1. Preparation using TAT-SNAP 25scFv antibody construct

[0085] A PCR product with a restriction enzyme site and TAT inserted was generated by using a primer for a previously screened SNAP 25scFv antibody (Table 1). 30 μL of each PCR product was treated with 3.14 μL buffer, 1 μL Sal I, 1 μL Xho I, and 4 μL distilled water, and reacted at 37°C for 1 hour, and then the DNA was isolated to ensure the insert to be inserted into the vector. After the pET28a (+) vector was transformed into DH5α competent cells, it was smeared on an LB plate supplemented with kanamycin and cultured at 37°C for 16 hours. The colony was taken out the next day and inoculated into LB medium supplemented with kanamycin, and then cultured at 37°C for 16 hours. The next day, the vector was isolated using a mini-prep kit, and then 30 μL of the vector was treated with 3.14 μL buffer, 1 μL Sal I, 1 μL Xho I, 1 μL CIP, and 3 μL distilled water, and purified after reacting at 37°C for 1 hour. The concentrations of the purified vector and insert were measured by nanodrop, and a 16-hour ligation reaction was performed at room temperature using T4 ligase according to the ratio of vector to insert. After the ligation reaction, transformation was performed in DH5α competent cells, and then smeared on LB plates supplemented with kanamycin, and cultured at 37°C for 16 hours. The colony was taken out the next day, inoculated into LB media supplemented with kanamycin, and cultured at 37°C for 16 hours. The next day, in order to confirm whether the insert had been inserted, the plasmid was isolated, restricted with Sal I and Xho I, and electrophoresed on 1% agarose gel to confirm the band.

[0086] Table 1

[0087]

[0088] 2. Purification of TAT-anti-SNAP 25 scFv Antibody

[0089] The cloned TATSNAP 25 scFv antibody was transformed into BL21 (DE3) E. coli host. The transformant was cultured in LB medium containing kanamycin until OD 600 The value reached 0.6, and the expression was induced by treatment with 0.5mM IPTG at 16°C. The cells obtained by centrifugation of the culture medium were suspended in a lysis buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl), and then crushed with an ultrasonic grinder and centrifuged to obtain the supernatant. The TAT-SNAP 25scFv antibody protein was purified using a resin with affinity for Ni-NTA, and the size of the protein was confirmed to be about 30kDa ( Figure 2 ).

[0090] Example 4 Cytotoxicity test of cell-permeable SNAP 25scFv antibody protein

[0091] In order to understand the cytotoxicity of TAT-SNAP 25scFv antibody, mammalian neural cell PC12 cells were cultured at 37°C in a CO2 incubator. After culture, TAT-SNAP 25scFv antibody was treated at different concentrations and then further cultured under the same culture conditions. After treatment with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) solution and culture, the culture medium was removed, dimethyl sulfoxide (DMSO: Dimethyl sulfoxide) was added and mixed thoroughly, and the absorbance was measured at 570nm using an ELISA reader system. The values ​​are shown in Table 2. As shown in Table 2, when the TAT-SNAP 25scFv antibody was treated at concentrations of 0.01ppm, 0.1ppm, 1ppm, 10ppm, 50ppm, and 100ppm, it was confirmed that mammalian neurons showed almost no deformation of cell shape and no change in cell survival rate up to a concentration of 100ppm. Therefore, it was found that the TAT-SNAP 25scFv antibody is a non-cytotoxic substance up to a concentration of 100ppm.

[0092] Table 2

[0093]

[0094] Example 5 Experiment on the ability of cell-permeable SNAP 25 scFv antibody to inhibit SNARE complex formation

[0095] In order to confirm whether the TAT-SNAP 25scFv antibody inhibits the formation of the SNARE complex, native-PAGE analysis was performed. It was confirmed whether the complex formed when SNAP 25, Syntaxin1A, and VAMP2 proteins (LSbio) as SNARE proteins were mixed at a concentration of 1:1:1 (1μg) was inhibited by the addition of TAT-SNAP 25scFv antibody. 1μg of each protein was added, treated with anti-SNAP 25scFv antibodies at different concentrations (0.001μg, 0.01μg, 0.1μg, 1μg, 10μg, 20μg), mixed thoroughly, and then reacted at 4°C for 1 hour. When the reaction was completed, the sample buffer was added to terminate the reaction, and then the formation of the SNARE complex was confirmed on 10% native-PAGE. The results are shown in Figure 3 , it can be seen that TAT-SNAP 25scFv antibody can effectively inhibit the formation of SNARE complex.

[0096] Example 6 Evaluation of the Inhibition of MMP-1 Expression by Cell-Permeable Anti-SNAP 25 scFv

[0097] In order to study the effect of TAT-SNAP 25scFv antibody on collagen production, the real-time PCR method was used to test the inhibitory effect of TAT-SNAP 25scFv antibody on MMP-1 activity. PC12 cells, which are mammalian neural cells, were cultured in a CO2 incubator at 37°C. After culture, UVA was irradiated using a UV irradiator system. Then, the cells were treated with 10ppm of TAT-SNAP25scFv antibody and 100ppm of adenosine as a positive control group, and then further cultured under the same culture conditions. After culture, the cells were extracted with 300μL of TRIzol and transferred to a 1.5mL tube, to which 50μL of chloroform was added, mixed and placed at room temperature for 5 minutes. After that, centrifuge at 4°C and 15,000rpm for 15 minutes, move the supernatant to a new tube, mix with the same amount of 2-propanol, place at room temperature for 5 minutes, and centrifuge at 4°C and 12,000rpm for 20 minutes. After centrifugation, discard 2-propanol, add 300μL of 75% ethanol, and centrifuge at 4°C and 10,000rpm for 10 minutes. Discard 75% ethanol and dry the RNA pellet at room temperature to remove the remaining ethanol. Add 30μL of purified water treated with DEPC to the pellet and dissolve it, then quantify at 260nm. RT-PCR was performed using 1μg of total RNA and TOPscript RT dry mix. MMP-1 and GAPDH used in real-time PCR were synthesized and used at Macrogen, and the base sequences are shown in Table 3 below. Real-time PCR was performed using TOPreal™ Qpcr 2X PreM IX. Figure 4 As shown, TAT-SNAP25scFv antibody inhibited MMP-1 collagenase, which is responsible for the generation of wrinkles due to UV rays. When treated with 10 ppm of TAT-SNAP 25scFv antibody, an effect similar to that of the control group treated with 100 ppm was exhibited.

[0098] Table 3

[0099]

[0100] Example 7 Cell and skin penetration analysis of cell-permeable SNAP 25 scFv antibody

[0101] 1. Cell penetration analysis of TAT-SNAP 25 scFv antibody

[0102] To confirm the cell penetration of TAT-SNAP 25scFv antibody, PC12 cells were cultured in 6-well plates, then replaced with 1.5 mL of fresh culture medium without FBS, and treated with various concentrations of TAT-SNAP 25scFv antibody. After 1 hour of treatment, the cells were fully washed with PBS and recovered, and the extent of TAT-SNAP 25scFv antibody penetration into the cells was confirmed by Western blot analysis. In order to confirm whether the TAT-SNAP 25scFv antibody that penetrated into the cells was confirmed at the correct position (size), the TAT-SNAP 25scFv antibody (control) purified by pure water was also subjected to electrophoresis. Figure 5 As shown, it was confirmed that the TAT-SNAP 25 scFv antibody efficiently permeated into cells in a concentration-dependent manner.

[0103] 2. Skin penetration analysis of TAT-SNAP 25scFv antibody

[0104] In order to confirm the skin penetration of TAT-SNAP 25scFv antibody, it was confirmed by tissue staining of pig skin. The pig skin was treated with 10μg of TAT-SNAP 25scFv antibody and cultured in a 37°C, CO 2 incubator for 16h. After fixing the pig skin with 4% formalin, paraffin blocks were prepared and 5μm of tissue was cut using a microtome. Then, the tissue was fixed on a slide and the paraffin was removed. After a hydration process, the tissue sections were blocked for 30min. The blocked tissue was reacted with anti-His HRP antibody at room temperature for 1h. After washing with PBST, it was reacted with DAB-chromogen solution for 5min, then stained with H&E staining and observed with an optical microscope. Figure 6 The results are a comparison of the skin permeability of SNAP 25 scFv antibody and TAT-SNAP 25 scFv antibody. It was confirmed that SNAP 25 scFv antibody was not delivered into pig skin tissue at all, while anti-SNAP 25 scFv antibody had effective skin delivery ability.

[0105] Example 8 Experiment on the inhibitory effect of cell-penetrating SNAP 25scFv antibody on active oxygen species

[0106] In order to confirm the intracellular reactive oxygen species (ROS) inhibitory effect of TAT-SNAP 25scFv antibody, PC12 cells, which are mammalian neural cells, were treated with TAT-SNAP25scFv antibody, and the intracellular reactive oxygen species content was measured by fluorescence staining. PC12 cells seeded in 96-well plates were cultured in a CO2 incubator at 37°C and then treated with TAT-SNAP25scFv antibody (10ppm, 20ppm, 50ppm, 100ppm). After culturing for 2h, 0.2mM hydrogen peroxide was added to each well, and then further cultured under the same culture conditions. 20μM carboxyl-H2DCF-DA was added and reacted at 37°C for 30min. After washing thoroughly with PBS, 100μL PBS was added, and then the fluorescence was measured at 485 / 525nm using an ELISA reader system, and the values ​​are shown in Table 4. As shown in Table 4, it was found that the TAT-SNAP25scFv antibody effectively inhibited the generation of ROS.

[0107] Table 4

[0108]

[0109] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.

[0110] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. Use of a protein that inhibits the SNARE complex in the preparation of cosmetics for preventing or improving skin wrinkles, characterized in that: The protein that inhibits the SNARE complex includes a SNAP 25 antibody; the antibody includes: 1) a light chain variable region, comprising a light chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO.1, a light chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO.2, and a light chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO.3; 2) a heavy chain variable region, comprising a heavy chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO.4, a heavy chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO.5, and a heavy chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO.6; 3) Fc region, wherein the sequence of the Fc region is the sequence of the Fc constant region of any antibody that binds to the SNAP 25 protein.

2. A SNAP 25 antibody, characterized in that: The antibody is the protein sequence according to claim 1.

3. A SNAP 25 fusion antibody, characterized in that: The invention comprises a fragment in which the TAT peptide shown in SEQ ID NO. 7 is bound to the antibody according to claim 2.

4. A nucleic acid molecule encoding the antibody of claim 2.

5. A biomaterial comprising: 1) A recombinant expression vector comprising the nucleic acid molecule of claim 3; 2) Cells transformed with the recombinant expression vector described in 1).

6. A cosmetic composition for preventing or improving skin wrinkles, characterized in that: The active ingredient comprises the antibody according to claim 2.

7. An antioxidant cosmetic composition, characterized in that: Comprising the antibody according to claim 2 or 3.

8. A composition for diagnosing skin pigmentation diseases, characterized in that: Comprising the antibody according to claim 2 or 3.

9. A pharmaceutical composition for preventing or treating skin wrinkles, characterized in that: Comprising the antibody described in claims 2 to 3.